Revolution Medicines/$RVMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Ticker
$RVMD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
616
ISIN
US76155X1000
Website
RVMD Metrics
BasicAdvanced
$7.2B
-
-$4.02
1.11
-
Price and volume
Market cap
$7.2B
Beta
1.11
52-week high
$60.59
52-week low
$29.17
Average daily volume
2.8M
Financial strength
Current ratio
13.459
Quick ratio
13.258
Long term debt to equity
5.84
Total debt to equity
6.464
Profitability
EBITDA (TTM)
-782.745
Effective tax rate (TTM)
0.11%
Management effectiveness
Return on assets (TTM)
-23.09%
Return on equity (TTM)
-36.68%
Valuation
Price to book
3.45
Price to tangible book (TTM)
3.57
Price to free cash flow (TTM)
-11.107
Free cash flow yield (TTM)
-9.00%
Free cash flow per share (TTM)
-346.63%
Growth
Earnings per share change (TTM)
8.38%
3-year earnings per share growth (CAGR)
12.60%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Bulls say / Bears say
Revolution Medicines secured a $2 billion flexible funding agreement with Royalty Pharma to support the global development and commercialization of its RAS(ON) inhibitor portfolio, enhancing its financial position for advancing cancer therapies. (tradingview.com)
Analysts have set an average price target of $67.08 for Revolution Medicines, indicating strong confidence in the company's growth prospects. (etfdailynews.com)
Institutional investors, including Vanguard Group Inc. and Janus Henderson Group PLC, have significantly increased their stakes in Revolution Medicines, reflecting robust institutional confidence in the company's future. (defenseworld.net)
Wellington Management Group LLP reduced its holdings in Revolution Medicines by 5.1%, potentially signaling concerns about the company's short-term performance. (marketbeat.com)
The biotech sector is experiencing significant turmoil due to policy uncertainties under President Donald Trump's administration, including inconsistent drug approvals by the FDA and aggressive calls for drug price reductions, which could negatively impact companies like Revolution Medicines. (ft.com)
Investors largely dismissed U.S. President Donald Trump's threat to impose a 200% tariff on pharmaceuticals, judging it as unlikely to materialize. While shares in major European and Indian pharmaceutical companies initially dipped, they quickly stabilized. Analysts like Emily Field from Barclays labeled the threat as rhetorical, echoed by others who found the proposal impractical and potentially inflationary. Despite supplying around 40% of the U.S.'s generic drugs, India's pharma market remained steady, with minimal stock volatility. Trump's tariff threat coincides with ongoing U.S. investigations into the national security risks of foreign medicine production and proposed drug pricing reforms, including most-favored-nation pricing. Trump also suggested giving pharma companies up to 18 months to shift production back to the U.S., a timeline criticized as unrealistic due to regulatory and logistical hurdles. Capstone analysts warned that such harsh tariffs could cause drug shortages and significantly raise U.S. drug prices. Many U.S. and European drugmakers have nonetheless announced investments aimed at appeasing the administration. The tariff threat is viewed as part of broader negotiation strategies on domestic pricing and trade, especially amid talks of a trade deal between the U.S. and India, which faces multiple tariff risks. (ft.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
RVMD News
AllArticlesVideos
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates
GlobeNewsWire·2 days ago
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
GlobeNewsWire·2 weeks ago
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Reuters·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Revolution Medicines stock?
Revolution Medicines (RVMD) has a market cap of $7.2B as of July 11, 2025.
What is the P/E ratio for Revolution Medicines stock?
The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of July 11, 2025.
Does Revolution Medicines stock pay dividends?
No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Revolution Medicines dividend payment date?
Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Revolution Medicines?
Revolution Medicines (RVMD) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.